



# Tree of Knowledge™

INTERNATIONAL CORP

Comprehensive Pain Management  
Advanced Cannabinoid Medicine

---

Medically Focused  
Scientifically Based

**Investor Deck**

July 2019

CNSX : TOKI



# Disclaimer

This presentation is not, and under no circumstances is to be construed to be, an offering of securities. Neither this presentation, nor its delivery to the recipient, shall constitute an offer to sell, or the solicitation of an offer to buy the securities of the Company. It is provided solely for use by prospective investors in considering their interest.

The information in this presentation must be kept confidential at all times. By accepting this presentation, the recipient agrees that it will not copy, duplicate or distribute this presentation, in whole or in part, at any time without the Company's prior written consent. By your acceptance hereof, you covenant that neither you nor your agents, representatives, directors or employees will copy, reproduce or distribute this presentation or the information herein to others, in whole or in part, at any time, without the prior written consent of the Company, and that you will keep confidential this presentation, the information herein and any information otherwise obtained from the Company.

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. §811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug and, consequently, the Company's business may be deemed to operate in violation of U.S. federal law. While we intend to operate our business in compliance with State Cannabis laws and regulations, the regulatory regime is complex and evolving. We may not be able to obtain the necessary licenses, permits or authority to operate our business as currently contemplated, which may have a material adverse effect on our anticipated business strategy and results of operations. The enforcement of U.S. federal laws or changes in the enforcement priorities and policies, our inability to obtain licenses, permits or authority to operate our business as currently contemplated may adversely affect an investment in our securities.

The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Any securities offered will be offered only to institutional "accredited investors" within the meaning of Rule 501(a)(1), (2), (3) or (7) under the U.S. Securities Act under exemptions from such registration requirements. This presentation does not constitute an offer of securities, and no offer or sale of securities will be conducted in any jurisdiction where such offer or sale is prohibited.

THE OFFERED SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL SECURITIES REGULATOR PASSED ON THE ACCURACY OR ADEQUACY OF THIS OFFERING MEMORANDUM. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

**FORWARD-LOOKING INFORMATION** This presentation contains "forward-looking information" within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "an opportunity exists", "outlook", "prospects", "strategy", "intends", "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances.

Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. For further details on the forward looking information included in this presentation, see "Forward-Looking Statements" in the Preliminary Prospectus.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada.



# Disclaimer

**PURCHASERS' RIGHTS OF ACTION** The following rights are in addition to and without derogation from any other right or remedy which purchasers may have at law and are intended to correspond to the provisions of the relevant securities laws and are subject to the defences contained therein. The following summaries are subject to the express provisions of the applicable securities statutes and instruments in the below-referenced provinces and the regulations, rules and policy statements thereunder and reference is made thereto for the complete text of such provisions.

**ONTARIO INVESTORS** Under Ontario securities legislation, certain purchasers who purchase securities offered by an offering memorandum during the period of distribution will have a statutory right of action for damages, or while still the owner of the securities, for rescission against the issuer or any selling security holder if the offering memorandum contains a misrepresentation without regard to whether the purchasers relied on the misrepresentation. The right of action for damages is exercisable not later than the earlier of 180 days from the date the purchaser first had knowledge of the facts giving rise to the cause of action and three years from the date on which payment is made for the securities. The right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to exercise the right of action for rescission, the purchaser will have no right of action for damages against the issuer or any selling security holder. In no case will the amount recoverable in any action exceed the price at which the securities were offered to the purchaser and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, the issuer and any selling security holder will have no liability. In the case of an action for damages, the issuer and any selling security holder will not be liable for all or any portion of the damages that are proven to not represent the depreciation in value of the securities as a result of the misrepresentation relied upon.

These rights are not available for a purchaser that is (a) a Canadian financial institution or a Schedule III Bank (each as defined in National Instrument 45-106 - Prospectus Exemptions), (b) the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada), or (d) a subsidiary of any person referred to in paragraphs (a) and (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary.

These rights are in addition to, and without derogation from, any other rights or remedies available at law to an Ontario purchaser. The foregoing is a summary of the rights available to an Ontario purchaser. Not all defences upon which an issuer, selling security holder or others may rely are described herein. Ontario purchasers should refer to the complete text of the relevant statutory provisions.

**INVESTORS FROM OTHER PROVINCES** Securities legislation in certain other provinces and territories of Canada provides purchasers of securities with, in addition to any other right they may have at law, rights of rescission or damages, or both, where any document, purporting to describe the business and affairs of an issuer that has been prepared primarily for delivery to and review by a prospective purchaser so as to assist the prospective purchaser to make an investment decision in respect of securities and, in some cases, advertising and sales literature used in connection with the offering of the offered securities, contains a misrepresentation. For the purposes of this section, "misrepresentation" means:

- (a) an untrue statement of a fact that significantly affects, or would reasonably be expected to have a significant effect, on the market price or the securities of the Company (a "material fact"); or
- (b) an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it was made.

These rights must be exercised by purchasers of the offered securities within the prescribed time limits under applicable securities legislation. Purchasers should refer to the applicable provisions of the securities legislation of their province or territory for the full particulars of these rights or consult with their legal advisor.



# TOKI is establishing itself as a leading medical cannabis provider in Canada



Medical cannabis patient base of 15,000 and a total base of over 1M unique patients



EVR branded line of CBD products in stores with recent new orders in chains including Physician's Choice, Lucky's and Huckleberry's



Strategic partnerships with primary health and pain clinics across Canada including Jack Nathan Health (70+ clinics) and the Toronto Poly Clinic (26,000 patients) as well as with Canadian LP Northern Green



New production capabilities will ramp capacity and provide an uninterrupted supply of TOKI medical grade marijuana



R&D initiatives focused on new formulations and targeted delivery methods with leading Canadian and US academic and healthcare institutions including University of Toronto and McMaster



Patent pending on our flagship proven Medical Cannabis Opioid Reduction Program – a Proprietary training program providing physicians with an effective protocol for using medical cannabis to reduce patients' opioid use in treating chronic pain




## Our Mission

To provide chronic pain patients with high-quality, safe and effective healthcare through innovative products, services and alternative solutions.

## Our Vision

TOKI aims to enhance the quality of life of patients through research and development of innovative products





# Our leadership has the clinic and cannabis experience to drive growth

A diverse and representative *sample* of our expertise:



## Clinics

**GEORGE BARAKAT – BOARD MEMBER**

- Co-founder/CEO of Jack Nathan Health Inc., (1,000,000+ unique patients across Canada) which provides turnkey medical and dental clinics within Walmart stores
- Co-founder/CEO of Mass Med Media, digital media company helping brands engage consumers in large Canadian retail environs



## Pharma

**PETER SAUNDERS – BOARD MEMBER**

- Seasoned pharmaceutical industry executive
- Co-founded Oryx Pharmaceuticals Inc. growing it to sell for ~\$70M USD
- VP of Sales, Marketing and Government Affairs at MariCann
- Founding management member of the 14th approved licensed producer in Canada



## Medical

**DR. KEVIN ROD – MEDICAL ADVISOR TO THE BOARD OF DIRECTORS**

- Founder of Toronto Poly Clinic, a leading multidisciplinary specialty pain clinic
- Certified Family Physician credentialed in Chronic Pain Management by the CDN and US Academies of Pain Management
- Chair of Credentialing at the Canadian Academy of Pain Management
- Chronic Pain Assessors Team Lead for the College of Physicians and Surgeons of Ontario



## Start Ups / Rapid Expansion

**MICHAEL CARIDI – CHAIRMAN OF THE BOARD AND DIRECTOR OF BUSINESS DEVELOPMENT**

- Proven record for building start-up companies into national successes
- Developed \$100 million in real estate projects and provided construction services for a variety Fortune 500 clients and retailers
- Consulting for business development, biotech industry, and independent business ventures



## Clinics

**GARY PRIHAR – BOARD MEMBER, PRESIDENT CLINIC OPERATIONS**

- Past President, CFO and Co-Founder of Viva Care Medical
- Experienced Medical Services Executive, Operator and Manager
- Chartered Professional Accountant (CPA, CA) with over 10+ years of finance, audit and business consulting experience and has served as a Financial Controller for a TSX.V listed organization as well as a CFO of a private manufacturing firm



## Finance

**SPENCE WALKER – CFO**

- Chartered Profession Accountant with over 15 years' experience
- Experienced as both an auditor and a consultant for various reporting issuers in Canada and the US
- Partner at Kreston GTA a member of Kreston International, the 13th largest global accounting network



# TOKI is positioned for success across the cannabis value chain

Strategic Focus Areas:



## Clinics

Strategic partnership with multi-disciplinary primary and chronic pain clinics providing access to a large and loyal patient population



## Products

Development and distribution of formulated products for therapeutic purposes including natural health product alternatives



## Research and Development

Partner with LPs (Northern Green Canada) and academic institutions on research and development of patient focused innovative products which can be monetized across the healthcare environment



## TOKI's Clinic Partners

- Underpinned by two strategic clinic networks
  1. **Jack Nathan Medical** – 70+ primary healthcare clinics located in Walmart stores across Canada and another 6 in Mexico
  2. **The Toronto Poly Clinic** – 12 clinics (including partner clinics) specializing in chronic pain management
- Current medical cannabis patient base of 15,000 patients and growing
- Active channel for R&D and education





# The Toronto Poly Clinic

- TPC is a leading healthcare provider specializing in multidisciplinary specialty pain
- 12 Clinics in Ontario and Nova Scotia (including PCC Clinics)
- Industry leader in the ethical and controlled use of medical cannabis for the treatment of chronic illnesses
- Clinical testing with patient population

**MCORP™**  
 Medical Cannabis Opioid Reduction Program

Proprietary training program providing physicians with an effective protocol for using medical cannabis to reduce patients' opioid use in treating chronic pain.

**MCERP**  
 Medical Cannabis Education, Research and Best Practices

Education Materials  
 Training Sessions  
 Observational Studies  
 Advanced Clinical Trials

Strategic partnerships with other pain and physio therapy clinics providing access to **15,000 medical cannabis patients**

Preferred referral arrangement with Dr. Ho providing access to an additional 350k patients in Canada

Annual EBITDA \$1.8M+

Research partnerships with leading academic institutions including...





# Jack Nathan Medical Inc.

- TOKI and the Toronto Poly Clinic hold exclusivity relating to medical cannabis education, research and practice within existing Jack Nathan clinics
- Toronto Poly Clinic has the right of first refusal to setup and run pain clinics in all new Jack Nathan clinics
- In-clinic training of Doctors and allied healthcare professionals on Medical Cannabis products and participation in clinical research programs
- Strong and growing patient base and access to new markets



**3M** patient visits annually

**1M** unique patients and projected **40k** medical cannabis patients

**74** clinics in Walmart stores across **Canada** and **6** in **Mexico**





## Growing the Patient Base

Using its strength in clinics, to grow the patient base TOKI will:

- Rollout TPC cannabis education, research and medical practice in all 29 JNMI Ontario locations within 12 months
  - JNMI clinic in Vaughan, ON currently operational with TPC medical marijuana practice / services
- Expand to all existing JNMI locations (an additional 45 clinics across 5 provinces) within 2 years
- Rollout MCORP in Ontario within the next 6 months; expand to all provinces within 24 months
- **Projected total patient base** a result of these efforts: **50,000-70,000**
  - **Expected 20% growth** in patient base each year





# A new agreement with Northern Green Canada ensures a supply medical grade cannabis



**Grows the medical patient** base by investing in the education of both doctors and patients and reduces barriers to prescription writing and patient use



**Drives financial performance** through an industry leading revenue sharing agreement on jointly formulated (50%) and licensed strains (25%)



Provides an **uninterrupted supply** of medical grade marijuana (supply issues plague the market)



## About NGC:

- **Focus on developing and growing medical cannabis** products and conducting large scale cannabis trials
- **Federally licensed Canadian cannabis producer**
- **90,000 SF** state of the art **cultivation facility** in the Greater Toronto Area



## US Production

Current CBD Production: Spokane

Additional production in Arizona and Florida coming online shortly to increase capacity for TOKI's EVR CBD product lines

Formulations, processing, packaging

GMP qualified facility producing above industry standards

Allows EVR to move ahead of the curve in terms of quality and traceability

Currently supplying retailers including:





# Our products are distinguished by quality and traceability

TOKI's CBD products are developed using only the highest standards; product quality and purity is validated regularly using 3<sup>rd</sup> party testing

All EVR products are:



Organic



Non-GMO



Gluten Free



Pesticide Free



Microbial Free



Heavy Metal Free



From seed to sale, TOKI products are traceable

To view batch specific information customer can scan a QR code on all EVR products and verify lab results through a 3<sup>rd</sup> party



# Our Brand

## SUBLINGUAL

### Tinctures

Our L-Theanine Proprietary Bohan™ formulation contains a complex of adaptogens: L-Theanine, an amino acid derived from Green Tea produces a calming effect. Astragalus detoxifies, Ginseng increases blood circulation, Goji Berry rejuvenates, Artemisia is an antibacterial and Licorice Root helps to purify and decongest. Combined together, they unlock CBD's full potential for an individual's wellness.



## ACCURATE DOSING

### Airless Metered Pen

EVR's Airless Metered Pens are a proprietary medical dosing device containing full spectrum Organic Hemp Oil. This pen is offered with a variety of percentages of CBD.



## INGESTIBLES

### Capsules

Our L-Theanine Proprietary Bohan formulation is EVR's unique "Calming Adaptogen Complex". L-Theanine is an amino acid derived from Green Tea and is blended with other Asian Herbs such as Astragalus, Ginseng, Goji Berry, Artemesia, Licorice Root, Ledebouriella Divaricata Root and the Angelica Sinerisis Plant. Encapsulated in our patented beeswax technology.



## TOPICALS

### Balms & Creams

Topical application of a synergistic blend of CBD and naturally derived antioxidants for the best anti-inflammatory properties.





# Research and Development

Access to large number of patients puts TOKI in a unique position to conduct large scale, pharma grade studies and data collection.

As such we are committed to innovation and always researching new formulations and delivery methods

## R&D Initiatives Currently Underway With...

Cannabis Oil For Chronic Non-Cancer Pain Treatment



Evaluation of Interventions to Address the Opioid Crisis



Database for Cannabinoid Consumption and Study (DATACANN)





# Why TOKI?



One of the **largest and fastest growing medical cannabis patient bases** in Canada



**Partnership** agreements with **medical cannabis producers and clinics**



Our leadership team has a **proven track record** in building **high growth businesses** in the medical, pharma and clinic fields



Through our strategic partnerships we have **relationships with one of the world's largest retailer**



**Innovation is in our DNA** – currently engaged with leading educational institutions to develop new formulations and targeted delivery methods



Tree of  
Knowledge™  
INTERNATIONAL CORP